Unraveling the Mechanisms of S100A8/A9 in Myocardial Injury and Dysfunction

被引:0
|
作者
Xu, Yuanbo [1 ]
Wang, Yixuan [1 ]
Ning, Ke [1 ]
Bao, Yimin [1 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Sch Integrat Med, 1200 Cailun Rd, Shanghai 201203, Peoples R China
基金
中国国家自然科学基金;
关键词
myocardial damage; biomarker; inflammation; mitochondria; SIGNALING PATHWAY; RECEPTOR; 4; PROTEIN; S100; EXPRESSION; APOPTOSIS; INFLAMMATION; ACTIVATION; INFARCTION; MONOCYTES;
D O I
10.3390/cimb46090577
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
S100A8 and S100A9, which are prominent members of the calcium-binding protein S100 family and recognized as calprotectin, form a robust heterodimer known as S100A8/A9, crucial for the manifestation of their diverse biological effects. Currently, there is a consensus that S100A8/A9 holds promise as a biomarker for cardiovascular diseases (CVDs), exerting an influence on cardiomyocytes or the cardiovascular system through multifaceted mechanisms that contribute to myocardial injury or dysfunction. In particular, the dualistic nature of S100A8/A9, which functions as both an inflammatory mediator and an anti-inflammatory agent, has garnered significantly increasing attention. This comprehensive review explores the intricate mechanisms through which S100A8/A9 operates in cardiovascular diseases, encompassing its bidirectional regulatory role in inflammation, the initiation of mitochondrial dysfunction, the dual modulation of myocardial fibrosis progression, and apoptosis and autophagy. The objective is to provide new information on and strategies for the clinical diagnosis and treatment of cardiovascular diseases in the future.
引用
收藏
页码:9707 / 9720
页数:14
相关论文
共 50 条
  • [1] S100A8/A9 in Inflammation
    Wang, Siwen
    Song, Rui
    Wang, Ziyi
    Jing, Zhaocheng
    Wang, Shaoxiong
    Ma, Jian
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [2] S100A8/A9 and S100A9 reduce acute lung injury
    Hiroshima, Yuka
    Hsu, Kenneth
    Tedla, Nicodemus
    Wong, Sze Wing
    Chow, Sharron
    Kawaguchi, Naomi
    Geczy, Carolyn L.
    IMMUNOLOGY AND CELL BIOLOGY, 2017, 95 (05): : 461 - 472
  • [3] Role of S100A8/A9 in Sustained
    Singer, Benjamin H.
    Denstaedt, Scott J.
    Newstead, Michael W.
    Zeng, Xianying
    Standiford, Theodore J.
    ANNALS OF NEUROLOGY, 2017, 82 : S214 - S214
  • [4] S100A8/A9 in Myocardial Infarction: A Promising Biomarker and Therapeutic Target
    Cai, ZhuLan
    Xie, Qingwen
    Hu, Tongtong
    Yao, Qi
    Zhao, Jinhua
    Wu, Qingqing
    Tang, Qizhu
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [5] The role of S100A8/A9 in cardiac rupture after myocardial infarction
    Liu, Jidong
    Gai, Yusheng
    Wu, Dianshui
    Dong, Linping
    Li, Yuhui
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (09): : 8805 - 8810
  • [6] Structure/function studies of S100A8/A9
    Craig A. Harrison
    Mark J. Raftery
    Paul Alewood
    Carolyn L. Geczy
    Letters in Peptide Science, 1999, 6 : 359 - 369
  • [7] Structure/function studies of S100A8/A9
    Harrison, CA
    Raftery, MJ
    Alewood, P
    Geczy, CL
    LETTERS IN PEPTIDE SCIENCE, 1999, 6 (5-6): : 359 - 369
  • [8] Modulation of the inflammatory response by S100A8/A9
    Sperandio, M.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2014, 44 : 42 - 42
  • [9] Determination of S100A8 and A9 expression in ptergium
    Unal, B.
    Elpek, G.
    Ilhan, H. D.
    Bassorgun, C. I.
    Erin, N.
    VIRCHOWS ARCHIV, 2014, 465 : S298 - S298
  • [10] Therapeutic S100A8/A9 blockade inhibits myocardial and systemic inflammation and mitigates sepsis-induced myocardial dysfunction
    Gabriel Jakobsson
    Praveen Papareddy
    Henrik Andersson
    Megan Mulholland
    Ravi Bhongir
    Irena Ljungcrantz
    Daniel Engelbertsen
    Harry Björkbacka
    Jan Nilsson
    Adrian Manea
    Heiko Herwald
    Marisol Ruiz-Meana
    Antonio Rodríguez-Sinovas
    Michelle Chew
    Alexandru Schiopu
    Critical Care, 27